2013.08.22 沈琳：胃癌个体化药物治疗临床问题和研究进展

clinical efficacy in the intent-to-treat population-39145例复发转移性胃癌化疗联合放疗疗效-192002-2012 GC inpatients in Beijing cancer hospital-7improved PFS and OS in MET high patients-40HER2阳性率与肿瘤部位和类型有关-25FLO vs FLP-18Lauren分型不同分子标志物与意义-28Lauren分型与晚期患者预后-26in ...

2013.08.15 钟玉川：胆管癌的诊断与治疗

TNM分期-25病因-15病因-14TNM分期-24胆管癌的分类（一）-9胆管癌的分类（二）-10大体病理-16胆管癌的诊断与治疗-1胆管癌的临床表现-19非手术胆道引流-35非手术胆道引流-36概念区分-12概念-8肝管汇合的变异-6肝门部胆管癌Bismuth-Corlette临床分型-26肝门部胆管癌的改良临床分型-27肝门部胆管的位置-5肝门部胆管的位置-4肝外胆管的血供-7姑息性手术-34关于胆管的概念-2关于胆管 ...

2013.07.13 沈琳教授：晚期胃癌治疗的实用策略

沈琳教授：晚期胃癌治疗的实用策略

2013.07.13 陆舜教授：晚期非小细胞肺癌治疗的实用策略

陆舜教授：晚期非小细胞肺癌治疗的实用策略

2013.07.13 李进教授：晚期大肠癌治疗的实用策略

李进教授：晚期大肠癌治疗的实用策略

2013.07.13 江泽飞教授：乳腺癌化疗和内分泌治疗的实用策略

江泽飞教授：乳腺癌化疗和内分泌治疗的实用策略

2013.07.12 STAGE II COLON CANCER：SHOULD WE TREAT, AND, IF SO, WITH WHAT？

STAGE II COLON CANCER：SHOULD WE TREAT AND IF SO WITH WHAT？-3STAGE II COLON CANCER：SHOULD WE TREAT AND IF SO WITH WHAT？-2STAGE II COLON CANCER：SHOULD WE TREAT AND IF SO WITH WHAT？-1STAGE II COLON CANCER：SHOULD WE TREAT AND IF SO WITH WHAT？-4STAGE II COLON CANCER：SHOULD WE TREAT AND IF SO WITH WHAT？-6STAGE II CO ...

2013.07.12 Biologic Agent in the Treatment of Colorectal Cancer：Where We Are and Where We Need to Go

Biologic Agent in the Treatment of Colorectal Cancer：Where We Are and Where We Need to Go-1Biologic Agent in the Treatment of Colorectal Cancer：Where We Are and Where We Need to Go-3Biologic Agent in the Treatment of Colorectal Cancer：Where We Are and Where We Need to Go-4Biologic Agent in the Treatm ...

2013.07.12 Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer：German AIO study KRK-0306(FIRE-3)

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer：German AIO study KRK-0306(FIRE-3)-1Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab ...

2013.07.12 Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancerrandomized phase III non-inferiority trial

Bevacizumab continuation versus no continuation after first-line chemo-bev10Bevacizumab continuation versus no continuation after first-line chemo-bev12Bevacizumab continuation versus no continuation after first-line chemo-bev11Bevacizumab continu ...